LATS1

Summary

LATS1 (large tumor suppressor kinase 1, HGNC:6514) is a protein-coding gene on chromosome 6q25.1, encoding Serine/threonine-protein kinase LATS1 (O95835). Negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis.

The protein encoded by this gene is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis. The protein is phosphorylated in a cell-cycle dependent manner, with late prophase phosphorylation remaining through metaphase. The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity, indicating a role as a negative regulator of CDC2/cyclin A. In addition, the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding. Biochemical and genetic data suggest a role as a tumor suppressor. This is supported by studies in knockout mice showing development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatments.

Source: NCBI Gene 9113 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 131 total — 1 pathogenic, 2 likely-pathogenic
• Druggable target: yes — 32 molecules with ChEMBL bioactivity
• Cancer driver (intOGen): loss-of-function (tumor-suppressor-like) across 6 cancer types
• MANE Select transcript: NM_004690

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6514
Approved symbol	LATS1
Name	large tumor suppressor kinase 1
Location	6q25.1
Locus type	gene with protein product
Status	Approved
Aliases	WARTS
Ensembl gene	ENSG00000131023
Ensembl biotype	protein_coding
OMIM	603473
Entrez	9113

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 8 protein_coding, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000253339, ENST00000392273, ENST00000441107, ENST00000458696, ENST00000542720, ENST00000542747, ENST00000543571, ENST00000852165, ENST00000852166, ENST00000916254, ENST00000916255

RefSeq mRNA: 5 — MANE Select: NM_004690 NM_001270519, NM_001350339, NM_001350340, NM_001350392, NM_004690

CCDS: CCDS34551, CCDS59040

Canonical transcript exons

ENST00000543571 — 8 exons

Exon	Start	End
ENSE00001338727	149701779	149702266
ENSE00002281518	149658153	149662238
ENSE00002314788	149717849	149718101
ENSE00003487293	149695074	149695221
ENSE00003535606	149679875	149680457
ENSE00003559966	149683079	149684592
ENSE00003643935	149676260	149676366
ENSE00003683657	149676555	149676737

Expression profiles

Bgee: expression breadth ubiquitous, 263 present calls, max score 95.24.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.6257 / max 172.8738, expressed in 1777 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
76139	13.0281	1775
76140	0.5335	293
76138	0.0641	21

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
germinal epithelium of ovary	UBERON:0001304	95.24	gold quality
tibia	UBERON:0000979	95.22	gold quality
mucosa of paranasal sinus	UBERON:0005030	93.20	gold quality
gingival epithelium	UBERON:0001949	91.27	gold quality
epithelium of nasopharynx	UBERON:0001951	91.23	gold quality
nasopharynx	UBERON:0001728	91.21	gold quality
parietal pleura	UBERON:0002400	90.97	gold quality
visceral pleura	UBERON:0002401	90.76	gold quality
seminal vesicle	UBERON:0000998	90.75	gold quality
pigmented layer of retina	UBERON:0001782	90.20	gold quality
palpebral conjunctiva	UBERON:0001812	90.18	gold quality
eye	UBERON:0000970	90.17	gold quality
pleura	UBERON:0000977	89.82	gold quality
gingiva	UBERON:0001828	89.59	gold quality
mammary duct	UBERON:0001765	89.39	gold quality
amniotic fluid	UBERON:0000173	89.34	gold quality
cortical plate	UBERON:0005343	89.08	gold quality
jejunal mucosa	UBERON:0000399	89.01	gold quality
skin of hip	UBERON:0001554	88.61	gold quality
superficial temporal artery	UBERON:0001614	87.85	gold quality
esophagus squamous epithelium	UBERON:0006920	87.80	gold quality
ventricular zone	UBERON:0003053	87.58	gold quality
caput epididymis	UBERON:0004358	87.54	gold quality
adrenal tissue	UBERON:0018303	87.44	gold quality
ganglionic eminence	UBERON:0004023	87.27	gold quality
cauda epididymis	UBERON:0004360	86.90	gold quality
jejunum	UBERON:0002115	86.81	gold quality
mammalian vulva	UBERON:0000997	86.78	gold quality
oral cavity	UBERON:0000167	86.70	gold quality
corpus epididymis	UBERON:0004359	86.39	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.60

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
VEPH1	Repression

Upstream regulators (CollecTRI, top): CUX1, FOXC1, FOXL2, VEPH1, ZBED1

miRNA regulators (miRDB)

276 targeting LATS1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3163	100.00	77.23	8605
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-4775	99.98	75.00	6394

Literature-anchored findings (GeneRIF, showing 40)

• regulation of function on the mitosis apparatus by Cdc/cyclin B (PMID:12372621)
• molecular alterations found in soft tissue sarcoma (PMID:12379777)
• kpm negatively regulates cell growth by inducing G(2)/M arrest and apoptotic cell death through its kinase activity (PMID:12624101)
• WARTS plays a critical role in maintenance of ploidy through its actions in both mitotic progression and the G(1) tetraploidy checkpoint (PMID:15122335)
• LATS1 is a novel cytoskeleton regulator that affects cytokinesis by regulating actin polymerization through negative modulation of LIMK1. (PMID:15220930)
• Mst2, a STE20-family member and purported Hpo ortholog, phosphorylates and activates both Lats1 and Lats2 (PMID:15688006)
• Hypermethylation of the promoter region of LATS1 likely plays an important role in the down-regulation of LATS1 mRNA level in breast cancers, and breast cancers with a decreased expression of LATS1 mRNA level have a biologically aggressive phenotype. (PMID:15746036)
• Activation of Omi / HtrA2-mediated cell death is a potential mechanism for the tumor suppressive activity of WARTS. (PMID:16007220)
• Moderate overexpression of human LATS1 in cells exposed to microtubule poisons facilitated mitotic exit, and this activity required MOB1A. (PMID:16061636)
• LATS1 and LATS2 mRNA was down-regulated in astrocytoma by hypermethylation of the promoter (PMID:17049657)
• LATS1 inactivates YAP oncogenic function by suppressing its transcription regulation of cellular genes via sequestration of YAP in the cytoplasm after phosphorylation of YAP. (PMID:18158288)
• Expression profiling of genes induced by ectopic expression of YAP or by knockdown of LATS1 reveals a subset of the potential Drosophila Hippo pathway targets implicated in epithelial-to-mesenchymal transition. (PMID:18413746)
• Overexpression of YAP2 in cells promoted apoptosis, whereas the Mst2/Lats1-induced phosphorylation of YAP partially rescued the cells from apoptotic death. (PMID:18640976)
• collection of genes identified suggests that LATS1/2 function through diverse mechanisms and multiple signaling pathways including the Hippo signaling pathway, as well as the p53, Ras-ERK, or WNT networks, to inhibit tumor progression (PMID:19799973)
• YAP is phosphorylated by Lats on all of the five consensus HXRXXS motifs (PMID:20048001)
• ubiquitin E3 ligase ITCH physically and functionally associates with LATS1 (PMID:21212414)
• KIBRA associates with and activates Lats (large tumor suppressor) 1 and 2 kinases by stimulating their phosphorylation on the hydrophobic motif (PMID:21233212)
• study identifies E3 ubiquitin ligase Itch as a unique negative regulator of LATS1 and presents a possibility of targeting LATS1/Itch interaction as a therapeutic strategy in cancer. (PMID:21383157)
• LATS1 phosphorylates a phosphatase as does the yeast Dbf2 and demonstrate a novel role of LATS1 in controlling PLK1 at the G2 DNA damage checkpoint. (PMID:22641346)
• These results indicate that LATS1 is an important candidate tumor suppressor and its downregulated expression may contribute to glioma progression (PMID:22909338)
• In conclusion, N-terminally truncated Lats1 induced Lats2 downregulation and Yap protein accumulation, leading to chromosomal instability and tumorigenesis. (PMID:23230145)
• LATS1 is critical in mediating WWP1-induced increased cell proliferation in breast cancer cells. (PMID:23573293)
• Decreased expression of LATS1 in CRC is associated with promoter hypermethylation, but not microsatellite instability status (PMID:23885148)
• LATS1 and LATS2 mutations from cancers can lead to loss or reduction of their growth-inhibitory activity (PMID:24026096)
• Data indicate that the phosphorylation of Amot130 by LATS1/2 is found to be a key feature that enables it to inhibit Yes-associated protein (YAP) dependent signaling and cell growth. (PMID:24101513)
• Thus AMOT is a direct substrate of Lats1/2 mediating functions of the Hippo pathway in endothelial cell migration and angiogenesis. (PMID:24106267)
• These results collectively suggest that the Hippo pathway negatively regulates the actin-binding activity of Amot family members through direct phosphorylation. (PMID:24225952)
• These results indicate that LATS1 may play an important role in NSCLC, and may serve as a novel therapeutic target of non-small-cell lung cancer (NSCLC). (PMID:24682895)
• overexpression of Kibra rescues the increased cell migration and aberrant three-dimensional morphogenesis induced by knockdown of PTPN14, and this rescue is mediated through the activation of the upstream LATS1 kinase (PMID:25023289)
• NF2 loss-driven derepressed CRL4(DCAF1) promotes activation of YAP by inhibiting hippo pathwat kinases Lats1 and 2 in the nucleus. (PMID:25026211)
• ivation of MSH4 in germ cells may have played a role in the acquisition of additional TP53 and LATS1 germline mutations in a Li-Fraumeni family (PMID:25041856)
• LATS1 and LATS2 kinases play an important role in the regulation of NS5A function through site-specific post-translational modification and that phosphorylation of Ser/Thr71 is essential for optimal viral genome replication. (PMID:25044019)
• Cyclic stretch is associated with a JNK-dependent increase in binding of a LATS inhibitor, LIMD1, to the LATS1 kinase and that reduction of LIMD1 expression suppresses the activation of YAP by cyclic stretch. (PMID:25127217)
• Data indicate that tumour suppressor RASSF1A triggers large tumor suppressor kinase 1 (LATS)-CDK2 interaction and restricts CDK2 kinase activity towards BRCA2. (PMID:25218637)
• both LATS1 demethylation and overexpression of LATS1 downregulated the expression of Yes-associated protein (YAP), inhibited cell proliferation, induced cell apoptosis and cell cycle G1 arrest in 786-O cells (PMID:25270913)
• Findings suggest that polyomavirus middle T-antigen (PyMT) activates the Hippo pathway tumor suppressor Lats in a Src-dependent manner. (PMID:25362852)
• The control of LATS activation by angiotensin II and subsequent YAP localization is important for podocyte homeostasis and survival. (PMID:25393475)
• results reported here further support that LATS1/2 act normally as tumor suppressors and loss of their functions contributes to human cancer development (PMID:25482410)
• ITCH up-regulation and LATS1 down-regulation were closely associated with tumorigenesis and progression of SCC (PMID:25618271)
• These results demonstrated that as an inhibitor of YAP, LATS1 was decreased via downregulation of YAP using RNAi. This therefore indicated that the change in YAP levels in hepatocellular carcinoma cells may regulate LATS1 in a feedback manner. (PMID:25625370)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	lats1	ENSDARG00000003751
mus_musculus	Lats1	ENSMUSG00000040021
rattus_norvegicus	Lats1	ENSRNOG00000014916
drosophila_melanogaster	wts	FBGN0011739
caenorhabditis_elegans	wts-1	WBGENE00007047
caenorhabditis_elegans		WBGENE00011992

Paralogs (13): MAST4 (ENSG00000069020), MAST2 (ENSG00000086015), MAST3 (ENSG00000099308), SGK2 (ENSG00000101049), SGK3 (ENSG00000104205), DMPK (ENSG00000104936), MAST1 (ENSG00000105613), SGK1 (ENSG00000118515), MASTL (ENSG00000120539), LATS2 (ENSG00000150457), STK32B (ENSG00000152953), STK32C (ENSG00000165752), STK32A (ENSG00000169302)

Protein

Protein identifiers

Serine/threonine-protein kinase LATS1 — O95835 (reviewed: O95835)

Alternative names: Large tumor suppressor homolog 1, WARTS protein kinase

All UniProt accessions (3): O95835, H0YG09, Q6PJG3

UniProt curated annotations — full annotation on UniProt →

Function. Negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS1 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Acts as a tumor suppressor which plays a critical role in maintenance of ploidy through its actions in both mitotic progression and the G1 tetraploidy checkpoint. Negatively regulates G2/M transition by down-regulating CDK1 kinase activity. Involved in the control of p53 expression. Affects cytokinesis by regulating actin polymerization through negative modulation of LIMK1. May also play a role in endocrine function. Plays a role in mammary gland epithelial cell differentiation, both through the Hippo signaling pathway and the intracellular estrogen receptor signaling pathway by promoting the degradation of ESR1. Acts as an activator of the NLRP3 inflammasome by mediating phosphorylation of ‘Ser-265’ of NLRP3 following NLRP3 palmitoylation, promoting NLRP3 activation by NEK7.

Subunit / interactions. Complexes with CDK1 in early mitosis. LATS1-associated CDK1 has no mitotic cyclin partner and no apparent kinase activity. Binds phosphorylated ZYX, locating this protein to the mitotic spindle and suggesting a role for actin regulatory proteins during mitosis. Binds to and colocalizes with LIMK1 at the actomyosin contractile ring during cytokinesis. Interacts (via PPxY motif 2) with YAP1 (via WW domains). Interacts with MOB1A and MOB1B. Interacts with LIMD1, WTIP and AJUBA. Interacts with ESR1, DCAF1 and DCAF13; probably recruits DCAF1 and DCAF13 to ESR1 to promote ESR1 ubiquitination and ubiquitin-mediated proteasomal degradation. Interacts with STK3/MST2; this interaction is inhibited in the presence of DLG5. Interacts with SCRIB in the presence of DLG5. Interacts with WWTR1/TAZ. Interacts with WWC1, WWC2 and WWC3 (via their WW domains).

Subcellular location. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome. Spindle. Midbody. Spindle pole body.

Tissue specificity. Expressed in all adult tissues examined except for lung and kidney.

Post-translational modifications. Autophosphorylated and phosphorylated during M-phase of the cell cycle. Phosphorylated by STK3/MST2 at Ser-909 and Thr-1079, which results in its activation. Phosphorylated by MAP4Ks; in parallel to STK3/MST2 and resulting to its activation. Phosphorylation at Ser-464 by NUAK1 and NUAK2 leads to decreased protein level and is required to regulate cellular senescence and cellular ploidy.

Similarity. Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family.

Isoforms (2)

UniProt ID	Names	Canonical?
O95835-1	1	yes
O95835-2	2

RefSeq proteins (5): NP_001257448, NP_001337268, NP_001337269, NP_001337321, NP_004681* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR000961	AGC-kinase_C	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR009060	UBA-like_sf	Homologous_superfamily
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR015940	UBA	Domain
IPR017892	Pkinase_C	Domain
IPR042706	LATS1_STKc	Domain
IPR049761	LATS1-like_MobB	Domain
IPR050236	Ser_Thr_kinase_AGC	Family

Pfam: PF00069, PF00433, PF00627

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (54 total): compositionally biased region 11, sequence variant 9, region of interest 8, modified residue 7, helix 5, domain 3, mutagenesis site 3, short sequence motif 2, binding site 2, splice variant 2, chain 1, active site 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
7LWH	X-RAY DIFFRACTION	1.61
5BRK	X-RAY DIFFRACTION	2.3
4ZRK	X-RAY DIFFRACTION	2.32
5B5W	X-RAY DIFFRACTION	2.96

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95835-F1	55.88	0.16

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 828 (proton acceptor)

Ligand- & substrate-binding residues (2): 711–719; 734

Post-translational modifications (7): 246, 278, 464, 613, 674, 909, 1079

Mutagenesis-validated functional residues (3):

Position	Phenotype
464	abolishes phosphorylation by nuak1 and nuak2.
559	loss of interaction with yap1.
734	loss of kinase activity, autophosphorylation, increased ploidy, prolonged duration of mitosis and lack of p53 expression

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-2028269	Signaling by Hippo
R-HSA-162582	Signal Transduction

MSigDB gene sets: 379 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_DN, GOBP_CHROMOSOME_ORGANIZATION, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_REGULATION_OF_PROTEIN_POLYMERIZATION, GOBP_REGULATION_OF_PHOSPHORYLATION, GOBP_NEGATIVE_REGULATION_OF_KINASE_ACTIVITY, GOBP_INFLAMMATORY_RESPONSE, GOBP_SYNAPSE_ASSEMBLY, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_REGULATION_OF_DEVELOPMENTAL_GROWTH, GOBP_MAMMARY_GLAND_EPITHELIUM_DEVELOPMENT, GOBP_CELL_CYCLE_PHASE_TRANSITION, GOBP_GROWTH

GO Biological Process (27): G1/S transition of mitotic cell cycle (GO:0000082), G2/M transition of mitotic cell cycle (GO:0000086), sister chromatid segregation (GO:0000819), inner cell mass cell fate commitment (GO:0001827), inner cell mass cellular morphogenesis (GO:0001828), protein phosphorylation (GO:0006468), intracellular protein localization (GO:0008104), hormone-mediated signaling pathway (GO:0009755), regulation of transforming growth factor beta receptor signaling pathway (GO:0017015), keratinocyte differentiation (GO:0030216), regulation of actin filament polymerization (GO:0030833), regulation of intracellular estrogen receptor signaling pathway (GO:0033146), hippo signaling (GO:0035329), positive regulation of apoptotic process (GO:0043065), regulation of protein-containing complex assembly (GO:0043254), negative regulation of cyclin-dependent protein serine/threonine kinase activity (GO:0045736), regulation of organ growth (GO:0046620), cell division (GO:0051301), mammary gland epithelial cell differentiation (GO:0060644), negative regulation of canonical Wnt signaling pathway (GO:0090090), regulation of postsynaptic density assembly (GO:0099151), negative regulation of protein localization to nucleus (GO:1900181), positive regulation of NLRP3 inflammasome complex assembly (GO:1900227), regulation of ubiquitin-dependent protein catabolic process (GO:2000058), positive regulation of hippo signaling (GO:0035332), NLRP3 inflammasome complex assembly (GO:0044546), mitotic cell cycle phase transition (GO:0044772)

GO Molecular Function (12): magnesium ion binding (GO:0000287), protein serine/threonine kinase activity (GO:0004674), ATP binding (GO:0005524), protein kinase binding (GO:0019901), nuclear estrogen receptor binding (GO:0030331), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (11): spindle pole (GO:0000922), nucleus (GO:0005634), cytoplasm (GO:0005737), centrosome (GO:0005813), microtubule organizing center (GO:0005815), cytosol (GO:0005829), midbody (GO:0030496), postsynapse (GO:0098794), glutamatergic synapse (GO:0098978), spindle (GO:0005819), cytoskeleton (GO:0005856)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Signal Transduction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	6
mitotic cell cycle	2
mitotic cell cycle phase transition	2
inner cell mass cell differentiation	2
protein kinase activity	2
microtubule cytoskeleton	2
synapse	2
intracellular membraneless organelle	2
cell cycle G1/S phase transition	1
cell cycle G2/M phase transition	1
chromosome organization	1
nuclear chromosome segregation	1
cell fate commitment	1
cell morphogenesis	1
embryonic morphogenesis	1
phosphorylation	1
protein modification process	1
macromolecule localization	1
signal transduction	1
cellular response to hormone stimulus	1
transforming growth factor beta receptor signaling pathway	1
regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	1
regulation of cellular response to transforming growth factor beta stimulus	1
epidermal cell differentiation	1
skin development	1
regulation of actin polymerization or depolymerization	1
actin filament polymerization	1
regulation of protein polymerization	1
estrogen receptor signaling pathway	1
regulation of intracellular steroid hormone receptor signaling pathway	1
intracellular signal transduction	1
apoptotic process	1
regulation of apoptotic process	1
positive regulation of programmed cell death	1
regulation of cellular component biogenesis	1
regulation of cellular component organization	1
protein-containing complex assembly	1
regulation of cyclin-dependent protein serine/threonine kinase activity	1
cyclin-dependent protein serine/threonine kinase activity	1
negative regulation of cell cycle	1

Protein interactions and networks

STRING

1850 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LATS1	SAV1	Q9H4B6	998
LATS1	MOB1A	Q9H8S9	994
LATS1	MOB1B	Q7L9L4	993
LATS1	YAP1	P46937	974
LATS1	NF2	P35240	909
LATS1	LIMD1	Q9UGP4	860
LATS1	SCRIB	Q14160	855
LATS1	AMOT	Q4VCS5	852
LATS1	TEAD1	P28347	802
LATS1	ZYX	Q15942	795
LATS1	WWC1	Q8IX03	794
LATS1	RASSF1	Q9NS23	777
LATS1	WWTR1	Q9GZV5	759
LATS1	CCN1	O00622	753
LATS1	CCN2	P29279	741

IntAct

150 interactions, top by confidence:

A	B	Type	Score
YAP1	LATS1	psi-mi:“MI:0407”(direct interaction)	0.880
LATS1	YAP1	psi-mi:“MI:0217”(phosphorylation reaction)	0.880
LATS1	YAP1	psi-mi:“MI:0407”(direct interaction)	0.880
MOB1B	LATS1	psi-mi:“MI:0914”(association)	0.840
MOB1B	LATS1	psi-mi:“MI:0915”(physical association)	0.840
LATS1	MOB1B	psi-mi:“MI:0915”(physical association)	0.840
YAP1	MPDZ	psi-mi:“MI:0914”(association)	0.780
LATS1	MOB1A	psi-mi:“MI:0915”(physical association)	0.670
LATS1	YWHAH	psi-mi:“MI:0914”(association)	0.670
MOB1A	LATS1	psi-mi:“MI:0914”(association)	0.670
YWHAG	BLTP3B	psi-mi:“MI:2364”(proximity)	0.640
WWTR1	LATS1	psi-mi:“MI:0914”(association)	0.640
LATS1	WWTR1	psi-mi:“MI:0915”(physical association)	0.640
LATS1	CDK1	psi-mi:“MI:0914”(association)	0.630
CDK1	LATS1	psi-mi:“MI:0915”(physical association)	0.630
LATS1	CDK1	psi-mi:“MI:0915”(physical association)	0.630

BioGRID (732): LATS1 (Two-hybrid), LATS1 (Two-hybrid), LATS1 (Two-hybrid), LDOC1 (Two-hybrid), TFIP11 (Two-hybrid), MOAP1 (Two-hybrid), CEP76 (Two-hybrid), SSX2IP (Two-hybrid), FSD2 (Two-hybrid), SPERT (Two-hybrid), WWTR1 (Biochemical Activity), WWTR1 (Affinity Capture-Western), YAP1 (Protein-peptide), TAZ (Protein-peptide), ITCH (Protein-peptide)

ESM2 similar proteins: A0A0K3AV08, A7J1T0, A7J1T2, A7KAX9, A8X775, A8XU52, A9SY39, B4K6T8, G5EBZ8, G5ECQ3, G5EDE9, G5EEK3, G5EEW9, G5EGK6, O01700, O13839, O17862, O43283, O44757, O45797, O61366, O62090, O95835, P03949, P83510, Q03345, Q09314, Q09446, Q09994, Q11100, Q11181, Q17353, Q21341, Q3LRZ3, Q5R8X7, Q60JJ0, Q60LV7, Q61DP2, Q6E3D4, Q6GPD0

Diamond homologs: A2VDV2, A8WVU9, A8XJL7, E9PSL7, F4HPN2, F4HYG2, F4J6F6, M3TYT0, O01583, O13310, O14578, O15021, O45797, O54874, O60307, O75116, O77819, O94487, O95835, P00517, P05131, P05383, P0C1B1, P12688, P17612, P18961, P22204, P22694, P25321, P27791, P31034, P32328, P36887, P38679, P38938, P49025, P53894, P54265, P54644, P68180

SIGNOR signaling

41 interactions.

A	Effect	B	Mechanism
STK3	up-regulates	LATS1	phosphorylation
STK4	up-regulates	LATS1	phosphorylation
NUAK1	down-regulates	LATS1	phosphorylation
NUAK2	down-regulates	LATS1	phosphorylation
MOB1A	up-regulates	LATS1	binding
MOB1B	up-regulates	LATS1	binding
LATS1	down-regulates	WWTR1	phosphorylation
LATS1	“down-regulates quantity by repression”	VEPH1	“transcriptional regulation”
VEPH1	“down-regulates quantity by repression”	LATS1	“transcriptional regulation”
F2R	down-regulates	LATS1
LATS1	down-regulates	YAP1	phosphorylation
“sphingosine 1-phosphate”	down-regulates	LATS1
(R)-adrenaline	up-regulates	LATS1
GCG	up-regulates	LATS1
F-actin_assembly	down-regulates	LATS1
NF2	up-regulates	LATS1	binding
CyclinB/CDK1	up-regulates	LATS1	phosphorylation
LATS1	“down-regulates quantity by destabilization”	YAP1	phosphorylation
Mob1	up-regulates	LATS1	binding
STK3/4	up-regulates	LATS1	phosphorylation
DCAF1	“down-regulates quantity by destabilization”	LATS1	binding
Cullin4-RBX1-DDB1	“down-regulates quantity by destabilization”	LATS1	ubiquitination
PPM1F	“down-regulates activity”	LATS1	dephosphorylation
GNA13	“down-regulates activity”	LATS1	phosphorylation
ITCH	“down-regulates quantity”	LATS1	destabilization
LATS1	“up-regulates activity”	PPP1R12A	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 84 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	8	95.2×	7e-13
Signaling by Hippo	10	85.0×	3e-15
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	8	84.0×	2e-12
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	8	84.0×	2e-12
Activation of BH3-only proteins	8	62.1×	2e-11
FOXO-mediated transcription	8	42.0×	7e-10
RHO GTPases activate PKNs	8	39.6×	1e-09
Intrinsic Pathway for Apoptosis	8	36.6×	2e-09

GO biological processes:

GO term	Partners	Fold	FDR
hippo signaling	9	85.6×	4e-13
positive regulation of protein localization to nucleus	5	25.4×	3e-04
protein targeting	5	23.8×	4e-04
ERK1 and ERK2 cascade	5	20.6×	5e-04
positive regulation of stress fiber assembly	5	20.3×	5e-04
intracellular protein localization	12	16.3×	4e-09
G1/S transition of mitotic cell cycle	5	13.0×	3e-03
regulation of cell migration	5	10.2×	6e-03

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: loss-of-function (tumor-suppressor-like) across 6 cancer types — BCC, BRCA, CEAD, CESC, OVT, PAAD.

Clinical variants and AI predictions

ClinVar

131 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	2
Uncertain significance	101
Likely benign	4
Benign	1

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
1801795	NM_004690.4(LATS1):c.375A>T (p.Lys125Asn)	Pathogenic
619199	NM_004690.4(LATS1):c.2636G>A (p.Trp879Ter)	Likely pathogenic
800329	NM_004690.4(LATS1):c.2449G>A (p.Glu817Lys)	Likely pathogenic

SpliceAI

1885 predictions. Top by Δscore:

Variant	Effect	Δscore
6:149664573:T:A	donor_gain	1.0000
6:149676549:CTTTA:C	donor_loss	1.0000
6:149676550:TTTA:T	donor_loss	1.0000
6:149676551:TTA:T	donor_loss	1.0000
6:149676552:TAC:T	donor_loss	1.0000
6:149676553:A:AC	donor_gain	1.0000
6:149676554:C:CC	donor_gain	1.0000
6:149676733:GTCAC:G	acceptor_gain	1.0000
6:149676734:TCAC:T	acceptor_gain	1.0000
6:149676735:CAC:C	acceptor_gain	1.0000
6:149676735:CACC:C	acceptor_gain	1.0000
6:149676736:AC:A	acceptor_gain	1.0000
6:149676737:CC:C	acceptor_gain	1.0000
6:149676738:C:CC	acceptor_gain	1.0000
6:149676741:C:CT	acceptor_gain	1.0000
6:149676744:A:T	acceptor_gain	1.0000
6:149676746:C:CT	acceptor_gain	1.0000
6:149676747:A:T	acceptor_gain	1.0000
6:149679874:CCACT:C	donor_gain	1.0000
6:149695070:TCAC:T	donor_loss	1.0000
6:149695071:CACC:C	donor_loss	1.0000
6:149695072:A:AG	donor_loss	1.0000
6:149695073:C:CG	donor_loss	1.0000
6:149695218:TATC:T	acceptor_gain	1.0000
6:149695220:TC:T	acceptor_gain	1.0000
6:149695221:CCTGA:C	acceptor_gain	1.0000
6:149695225:A:AC	acceptor_gain	1.0000
6:149695225:A:C	acceptor_gain	1.0000
6:149695227:A:AC	acceptor_gain	1.0000
6:149695227:A:C	acceptor_gain	1.0000

AlphaMissense

7482 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:149661873:A:C	F1083L	1.000
6:149661873:A:T	F1083L	1.000
6:149661875:A:G	F1083L	1.000
6:149661882:G:C	F1080L	1.000
6:149661882:G:T	F1080L	1.000
6:149661884:A:G	F1080L	1.000
6:149661888:A:C	F1078L	1.000
6:149661888:A:T	F1078L	1.000
6:149661889:A:G	F1078S	1.000
6:149661890:A:G	F1078L	1.000
6:149661897:G:C	F1075L	1.000
6:149661897:G:T	F1075L	1.000
6:149661899:A:G	F1075L	1.000
6:149662005:A:C	F1039L	1.000
6:149662005:A:T	F1039L	1.000
6:149662006:A:C	F1039C	1.000
6:149662006:A:G	F1039S	1.000
6:149662007:A:G	F1039L	1.000
6:149662139:G:T	R995S	1.000
6:149676333:C:T	G937D	1.000
6:149676334:C:G	G937R	1.000
6:149676338:A:C	S935R	1.000
6:149676338:A:T	S935R	1.000
6:149676340:T:G	S935R	1.000
6:149676341:C:A	W934C	1.000
6:149676341:C:G	W934C	1.000
6:149676343:A:G	W934R	1.000
6:149676343:A:T	W934R	1.000
6:149676346:A:G	W933R	1.000
6:149676346:A:T	W933R	1.000

dbSNP variants (sampled 300 via entrez): RS1000058495 (6:149672025 A>G), RS1000101403 (6:149667329 G>A), RS1000132521 (6:149667645 T>C,G), RS1000146642 (6:149711066 C>A), RS1000260189 (6:149704972 C>T), RS1000394368 (6:149669529 G>A), RS1000405432 (6:149673922 G>A), RS1000449314 (6:149712640 C>A), RS1000463203 (6:149699760 T>C), RS1000465498 (6:149699004 T>A), RS1000536802 (6:149712575 T>G), RS1000592690 (6:149706381 G>A,C), RS1000603346 (6:149711270 C>A), RS1000647682 (6:149660538 C>A,G), RS1000693065 (6:149699763 A>T)

Disease associations

OMIM: gene MIM:603473 | disease phenotypes: MIM:254500

GenCC curated gene-disease

Mondo (5): myoepithelial tumor (MONDO:0002380), teratoma (MONDO:0002601), ependymoma (MONDO:0016698), malignant peritoneal mesothelioma (MONDO:0005512), plasma cell myeloma (MONDO:0009693)

Orphanet (4): Ependymoma (Orphanet:251636), Malignant peritoneal mesothelioma (Orphanet:168811), Multiple myeloma (Orphanet:29073), AL amyloidosis (Orphanet:85443)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST004635_15	Testicular germ cell tumor	2.000000e-09
GCST006631_15	Nicotine dependence and major depression (severity of comorbidity)	4.000000e-06
GCST010702_29	Subcortical volume (MOSTest)	7.000000e-11
GCST010703_317	Brain morphology (MOSTest)	7.000000e-22

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0007006	depressive symptom measurement
EFO:0009262	nicotine dependence symptom count
EFO:0004346	neuroimaging measurement

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D004806	Ependymoma	C04.557.465.625.600.380.290; C04.557.470.670.380.290; C04.557.580.625.600.380.290
D009101	Multiple Myeloma	C04.557.595.500; C14.907.454.460; C15.378.147.780.650; C15.378.463.515.460; C20.683.515.845; C20.683.780.650
D009208	Myoepithelioma	C04.557.435.585
D013724	Teratoma	C04.557.465.910

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL4523992 (PROTEIN FAMILY), CHEMBL6167 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

32 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 144,779 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1873475	IBRUTINIB	4	7,994
CHEMBL2103830	FOSTAMATINIB	4	3,841
CHEMBL2325741	CAPIVASERTIB	4	2,157
CHEMBL3301622	GILTERITINIB	4	2,395
CHEMBL502835	NINTEDANIB	4	8,545
CHEMBL535	SUNITINIB	4	79,020
CHEMBL608533	MIDOSTAURIN	4	7,259
CHEMBL1091644	LINSITINIB	3	1,446
CHEMBL2105728	CRENOLANIB	3	2,167
CHEMBL223360	LINIFANIB	3	3,925
CHEMBL274654	ORANTINIB	3	3,596
CHEMBL3137331	DEFACTINIB	3	1,229
CHEMBL38380	FASUDIL	3	11,953
CHEMBL522892	DOVITINIB	3	4,944
CHEMBL603469	LESTAURTINIB	3
CHEMBL91829	RUBOXISTAURIN	3	77
CHEMBL1721885	SU-014813	2	363
CHEMBL230011	TG100-115	2	1,504
CHEMBL2386889	SCH-900776	2	740
CHEMBL3137336	UPROSERTIB	2	1,624
CHEMBL495727	AT-9283	2
CHEMBL564829	MILCICLIB	2
CHEMBL572878	TOZASERTIB	2
CHEMBL1908397	KW-2449	1
CHEMBL3128043	PF-03758309	1
CHEMBL3544960	AT-13148	1
CHEMBL3545328	XL-019	1
CHEMBL4289017	PF-03814735	1
CHEMBL482967	CYC-116	1
CHEMBL494089	GSK-690693	1

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — NDR family

Most potent curated ligand interactions (14 total), top 14:

Ligand	Action	Affinity	Parameter
TRULI	Inhibition	9.7	pIC50
example 320 [WO2018198077A2]	Inhibition	9.15	pIC50
lestaurtinib	Inhibition	7.52	pKd
staurosporine	Inhibition	7.38	pKd
K-252a	Inhibition	7.17	pKd
PF-3758309	Inhibition	6.8	pKd
Lpi-1	Binding	6.61	pKd
AST-487	Inhibition	6.33	pKd
BI-847325	Inhibition	6.2	pKd
sunitinib	Inhibition	6.2	pKd
A-674563	Inhibition	5.96	pKd
midostaurin	Inhibition	5.96	pKd
defactinib	Inhibition	5.04	pKd
nintedanib	Inhibition	4.97	pKd

Binding affinities (BindingDB)

12 measured of 12 human assays (12 total across all organisms); most potent 12 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
Staurosporine	KD	1.7 nM
2-(3-methylpyrazolidin-4-yl)-N-[(1R)-1-phenylethyl]pyrido[3,4-d]pyrimidin-4-amine	IC50	28 nM	US-11458138: 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors
2-(3-methylpyrazolidin-4-yl)-N-(1-pyridin-4-ylethyl)pyrido[3,4-d]pyrimidin-4-amine	IC50	99 nM	US-11458138: 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors
N-[(1R)-1-phenylethyl]-2-pyrazolidin-4-ylpyrido[3,4-d]pyrimidin-4-amine	IC50	143 nM	US-11458138: 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors
PKC-412	KD	190 nM
(3Z)-4-amino-5-fluoro-3-[5-(4-methylpiperazino)-1,3-dihydrobenzimidazol-2-ylidene]carbostyril	KD	520 nM
(18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.1^{7,14}.0^{2,6}.0^{8,13}.0^{22,27}]nonacosa-1(28),2(6),7(29),8(13),9,11,22(27),23,25-nonaene-3,5-dione	KD	700 nM
2-pyrazolidin-4-yl-N-(1-pyridin-4-ylethyl)pyrido[3,4-d]pyrimidin-4-amine	IC50	797 nM	US-11458138: 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors
N-[4-({4-[(3-methyl-1H-pyrazol-5-yl)amino]-6-(4-methylpiperazin-1-yl)pyrimidin-2-yl}sulfanyl)phenyl]cyclopropanecarboxamide	KD	1100 nM
1-[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]urea	KD	1400 nM
5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(2S)-3-morpholin-4-yl-2-oxidanyl-propyl]-1H-pyrrole-3-carboxamide	KD	2600 nM
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	KD	3500 nM

ChEMBL bioactivities

866 potent at pChembl≥5 of 933 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.15	IC50	0.7	nM	CHEMBL4439972
9.12	IC50	0.76	nM	CHEMBL6082870
9.10	IC50	0.8	nM	CHEMBL4525078
9.10	IC50	0.8	nM	CHEMBL4447153
9.05	IC50	0.9	nM	CHEMBL4463018
9.05	IC50	0.9	nM	CHEMBL4463415
9.00	IC50	1	nM	CHEMBL4531857
9.00	IC50	1	nM	CHEMBL4472285
9.00	IC50	1	nM	CHEMBL4472973
9.00	IC50	1	nM	CHEMBL4592699
9.00	IC50	1	nM	CHEMBL4464251
9.00	IC50	1	nM	CHEMBL4533967
9.00	IC50	1	nM	CHEMBL4571192
9.00	IC50	1	nM	CHEMBL4551441
9.00	IC50	1	nM	CHEMBL4467179
9.00	IC50	1	nM	CHEMBL4518582
9.00	IC50	1	nM	CHEMBL4577857
9.00	IC50	1	nM	CHEMBL4472306
9.00	IC50	1	nM	CHEMBL4517252
9.00	IC50	1	nM	CHEMBL4471884
9.00	IC50	1	nM	CHEMBL4443335
9.00	IC50	1	nM	CHEMBL4577658
9.00	IC50	1	nM	CHEMBL4564805
9.00	IC50	1	nM	CHEMBL4576185
9.00	IC50	1	nM	CHEMBL4555291
9.00	IC50	1	nM	CHEMBL4450447
9.00	IC50	1	nM	CHEMBL4450439
9.00	IC50	1	nM	CHEMBL4547932
9.00	IC50	1	nM	CHEMBL4454440
9.00	IC50	1	nM	CHEMBL4444109
9.00	IC50	1	nM	CHEMBL4446730
9.00	IC50	1	nM	CHEMBL5914235
8.92	IC50	1.2	nM	CHEMBL4446217
8.92	IC50	1.2	nM	CHEMBL4590309
8.83	Kd	1.465	nM	CHEMBL3752910
8.74	IC50	1.8	nM	CHEMBL4456826
8.73	ED50	1.86	nM	CHEMBL3752910
8.72	IC50	1.9	nM	CHEMBL4483764
8.70	IC50	2	nM	CHEMBL4558207
8.70	IC50	2	nM	CHEMBL4471995
8.70	IC50	2	nM	CHEMBL4472817
8.70	IC50	2	nM	CHEMBL4439529
8.70	IC50	2	nM	CHEMBL4572019
8.70	IC50	2	nM	CHEMBL4547445
8.70	IC50	2	nM	CHEMBL4532021
8.70	IC50	2	nM	CHEMBL4514630
8.70	IC50	2	nM	CHEMBL4437570
8.70	IC50	2	nM	CHEMBL4462244
8.70	IC50	2	nM	CHEMBL4436796
8.70	IC50	2	nM	CHEMBL4447080

PubChem BioAssay actives

62 with measured affinity, of 499 total; 44 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148641: Binding affinity to human LATS1 incubated for 45 mins by Kinobead based pull down assay	kd	0.0015	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	1531743: Inhibition of human LATS1 using KKRNRRLSVA as substrate by [gamma-33P]-ATP assay	ic50	0.0128	uM
1-[6-(3,5-dichloro-4-hydroxyphenyl)-4-[[4-[(dimethylamino)methyl]cyclohexyl]amino]-1,5-naphthyridin-3-yl]ethanone	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0140	uM
(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0250	uM
(1S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)phenyl]ethanol	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0270	uM
1-cyclopropyl-3-[5-[6-(morpholin-4-ylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]urea	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0450	uM
6-(3-methylimidazol-4-yl)-4-(7H-purin-6-yl)-2,3-dihydro-1,4-thiazine	2019964: Inhibition of LATS1 (unknown origin)	ic50	0.0640	uM
4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0660	uM
methyl (15S,16R,18R)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene-16-carboxylate	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0670	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148641: Binding affinity to human LATS1 incubated for 45 mins by Kinobead based pull down assay	kd	0.0692	uM
4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[(3S)-piperidin-3-yl]methoxy]imidazo[4,5-c]pyridin-4-yl]-2-methylbut-3-yn-2-ol	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0740	uM
N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methylthieno[3,2-d]pyrimidin-4-yl)amino]-1,4-dihydropyrrolo[3,4-d]pyrazole-5-carboxamide	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.1570	uM
3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.1950	uM
Gilteritinib	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.2210	uM
4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide;hydrochloride	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.2610	uM
2-amino-2-cyclohexyl-N-[2-(1-methylpyrazol-4-yl)-9-oxo-3,10,11-triazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13),11-pentaen-6-yl]acetamide	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.3630	uM
N-[2-[4-[[4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-11-azatricyclo[6.2.1.02,7]undeca-2(7),3,5-trien-11-yl]-2-oxoethyl]acetamide	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.4060	uM
methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate	624963: Binding constant for LATS1 kinase domain	kd	0.4200	uM
1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[6-(methylamino)pyrimidin-4-yl]oxyphenyl]urea	435529: Binding constant for LATS1 kinase domain	kd	0.4700	uM
Sunitinib	435529: Binding constant for LATS1 kinase domain	kd	0.6300	uM
3-[3-[N-[4-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-1H-indol-6-yl]-N-ethylprop-2-ynamide	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.6350	uM
N,1,4,4-tetramethyl-8-[4-(4-methylpiperazin-1-yl)anilino]-5H-pyrazolo[4,5-h]quinazoline-3-carboxamide	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.6810	uM
5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	435529: Binding constant for LATS1 kinase domain	kd	0.8500	uM
4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.9550	uM
(2S)-1-[[5-(3-methyl-2H-indazol-5-yl)-3-pyridinyl]oxy]-3-phenylpropan-2-amine	624963: Binding constant for LATS1 kinase domain	kd	1.1000	uM
Midostaurin	435529: Binding constant for LATS1 kinase domain	kd	1.1000	uM
5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine	624963: Binding constant for LATS1 kinase domain	kd	1.6000	uM
Ibrutinib	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	1.8840	uM
1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea	624963: Binding constant for LATS1 kinase domain	kd	2.1000	uM
Fostamatinib	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	2.1570	uM
(18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.17,14.02,6.08,13.022,27]nonacosa-1(28),2(6),7(29),8,10,12,22,24,26-nonaene-3,5-dione	435529: Binding constant for LATS1 kinase domain	kd	2.6000	uM
1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	2.7680	uM
3-[2,4-dimethyl-5-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	3.0110	uM
5-cyano-N-[2-(cyclohexen-1-yl)-4-[1-[2-(dimethylamino)acetyl]piperidin-4-yl]phenyl]-1H-imidazole-2-carboxamide;hydrochloride	624963: Binding constant for LATS1 kinase domain	kd	3.3000	uM
N-[(2S)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-1-methylpyrazol-5-yl)furan-2-carboxamide	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	3.5920	uM
N-[4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]phenyl]pyrrolidine-2-carboxamide	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	3.7900	uM
7-[3-(azetidin-1-yl)cyclobutyl]-5-(3-phenylmethoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	3.8790	uM
5-(1,4-diazepan-1-ylsulfonyl)isoquinoline	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	4.1700	uM
3-[2,4-diamino-7-(3-hydroxyphenyl)pteridin-6-yl]phenol	624963: Binding constant for LATS1 kinase domain	kd	4.5000	uM
6-bromo-3-(1-methylpyrazol-4-yl)-5-[(3R)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	4.6160	uM
[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone	624963: Binding constant for LATS1 kinase domain	kd	5.0000	uM
N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide	435529: Binding constant for LATS1 kinase domain	kd	5.5000	uM
N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	9.0500	uM
Capivasertib	1425033: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	14.1030	uM

CTD chemical–gene interactions

46 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
XMU-MP-1	increases phosphorylation, decreases phosphorylation, decreases reaction, increases expression	2
sodium arsenite	affects binding, increases reaction, increases abundance, increases expression	2
Cadmium Chloride	decreases phosphorylation, decreases expression, increases abundance, decreases activity	2
aristolochic acid I	decreases expression	1
caulerpin	increases phosphorylation	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
napabucasin	decreases expression	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
gingerol	increases expression	1
mono-(2-ethylhexyl)phthalate	decreases reaction, increases stability	1
zinc chloride	decreases phosphorylation	1
manganese chloride	increases abundance, increases expression	1
coumarin	increases phosphorylation	1
nitazoxanide	increases expression	1
N,N,N’,N’-tetrakis(2-pyridylmethyl)ethylenediamine	affects binding, decreases reaction	1
evodiamine	increases phosphorylation, decreases reaction, increases expression	1
licochalcone A	decreases expression, increases expression	1
ginsenoside Rg3	increases expression	1
jinfukang	decreases expression	1
Decitabine	affects methylation, affects expression	1
Sunitinib	increases expression	1
Leflunomide	increases expression	1
Air Pollutants	increases abundance, increases expression	1
Arsenic	increases abundance, increases expression	1
Arsenicals	affects response to substance, increases abundance	1
Benzo(a)pyrene	decreases methylation	1
Cadmium	decreases expression, increases abundance	1
Caffeine	affects phosphorylation	1
Chlorpromazine	increases phosphorylation	1

ChEMBL screening assays

207 unique, capped per target: 207 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4420664	Binding	Inhibition of LATS in human HaCaT cells assessed as reduction in YAP phosphorylation level incubated for 2 hrs by HTRF assay	6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors

Cellosaurus cell lines

15 cell lines: 13 cancer cell line, 1 transformed cell line, 1 induced pluripotent stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_1430	MSTO-211H	Cancer cell line	Male
CVCL_B1AF	Abcam THP-1 LATS1 KO	Cancer cell line	Male
CVCL_B8JK	Abcam HCT 116 LATS1 KO	Cancer cell line	Male
CVCL_B8Y8	Abcam MCF-7 LATS1 KO	Cancer cell line	Female
CVCL_B9LU	Abcam A-549 LATS1 KO	Cancer cell line	Male
CVCL_D7TF	Ubigene A-549 LATS1 KO	Cancer cell line	Male
CVCL_D8P3	Ubigene HCT 116 LATS1 KO	Cancer cell line	Male
CVCL_D9IE	Ubigene HEK293 LATS1 KO	Transformed cell line	Female
CVCL_E0GC	Ubigene HeLa LATS1 KO	Cancer cell line	Female
CVCL_E0ZC	Ubigene MSTO-211H LDHA KO	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00104104	PHASE4	COMPLETED	A Multiple Myeloma Trial in Patients With Bone Metastases
NCT00211211	PHASE4	COMPLETED	FREE Study - Fracture Reduction Evaluation
NCT00242528	PHASE4	WITHDRAWN	Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.
NCT00257114	PHASE4	COMPLETED	Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
NCT00352703	PHASE4	COMPLETED	PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
NCT00361140	PHASE4	COMPLETED	Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
NCT00622505	PHASE4	COMPLETED	Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
NCT00652041	PHASE4	COMPLETED	Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma
NCT00733538	PHASE4	COMPLETED	Stage I Multiple Myeloma Treatment
NCT01087008	PHASE4	COMPLETED	Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
NCT01249690	PHASE4	UNKNOWN	Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
NCT01410929	PHASE4	WITHDRAWN	Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma
NCT01731886	PHASE4	COMPLETED	Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
NCT01868828	PHASE4	UNKNOWN	A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma
NCT02268890	PHASE4	COMPLETED	A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma
NCT02286830	PHASE4	COMPLETED	Prolonged Protection From Bone Disease in Multiple Myeloma
NCT02559154	PHASE4	UNKNOWN	Modified Bortezomib-based Combination Therapy for Multiple Myeloma
NCT02577783	PHASE4	UNKNOWN	PDD vs PAD to Treat Initially Diagnosed MM
NCT02773550	PHASE4	TERMINATED	Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma
NCT02958969	PHASE4	COMPLETED	Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
NCT03173092	PHASE4	TERMINATED	A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
NCT03619252	PHASE4	COMPLETED	Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents
NCT03768960	PHASE4	COMPLETED	A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
NCT03829371	PHASE4	ACTIVE_NOT_RECRUITING	STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
NCT03908138	PHASE4	UNKNOWN	RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma
NCT04217967	PHASE4	COMPLETED	Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
NCT04952766	PHASE4	COMPLETED	Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
NCT04989140	PHASE4	UNKNOWN	Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide
NCT05183139	PHASE4	WITHDRAWN	A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma
NCT05201781	PHASE4	RECRUITING	A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05429515	PHASE4	NOT_YET_RECRUITING	Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury
NCT05511428	PHASE4	COMPLETED	Home Based Daratumumab Administration for Patients With Multiple Myeloma
NCT05545202	PHASE4	UNKNOWN	A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
NCT05555329	PHASE4	COMPLETED	Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study
NCT05722405	PHASE4	RECRUITING	Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
NCT05855122	PHASE4	UNKNOWN	Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
NCT05944783	PHASE4	NOT_YET_RECRUITING	Bioequivalence Studies of Dasatinib 100 Mg
NCT06057402	PHASE4	RECRUITING	Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
NCT06251076	PHASE4	RECRUITING	Plan Development for Giving Teclistamab in the Outpatient Setting